Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HMBD 501

X
Drug Profile

HMBD 501

Alternative Names: ENV-501; ENV-ONC-501; HMBD-501

Latest Information Update: 06 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hummingbird Bioscience
  • Class Alkaloids; Antineoplastics; Camptothecins; Drug conjugates; Immunoconjugates; Immunoglobulin Fc fragments
  • Mechanism of Action DNA topoisomerase I inhibitors; ERBB-3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 02 Nov 2023 Endeavor BioMedicines plans a clinical trial for solid tumours in 2024
  • 19 Oct 2023 Endeavor BioMedicines in-licenses HMBD 501 from Hummingbird Bioscience
  • 19 Oct 2023 Hummingbird Bioscience plans to file investigational new drug (IND) application in first half of 2024
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top